Decision Resources Research Reports

Title	Published	Price
Pharma Antes Up: Investment and Business Trends Driving Biotechnology By: Decision Resources Introduction: Faced with weak pipelines, poor R&D productivity, expiring patents, and public and regulatory pressure over safety, major pharmaceutical companies are turning to the biotech industry for innovation. Much as in the late 1990s, Big \| more...	6/15/2007	$1,112.50
2007 Chartbook of International Pharmaceutical Prices By: Decision Resources Introduction: Pharmaceutical companies are increasingly subjected to the dynamics of a globalized pharmaceutical market, and drug pricing and reimbursement continue to vary widely country to country. In a price-sensitive environment such as this, pharmaceutical companies \| more...	6/14/2007	$2,250.00
Will Metabolic Syndrome Emerge as a Commercial Market? By: Decision Resources Introduction: Is metabolic syndrome a disease itself—or merely a grouping of diagnoses that identify a person as being at increased risk for cardiovascular disease? Current medical practice, regulatory guidance, and drug development appear to be \| more...	6/14/2007	$2,250.00
SPECIAL REPORT: How Will the Withdrawal of Generic Albuterol Change the U.S. Respiratory Disease Market? By: Decision Resources Introduction: The albuterol inhaler market in the United States will soon change from low-value to signifi cant. The only MDIs sold will be branded HFA formulations; CFC propellants will be eliminated. Because the new HFA \| more...	6/8/2007	$2,250.00
Specialty Pharma: Guide to Success at the New Frontier By: Decision Resources Recently catapulted into the pharmaceutical industry limelight, Specialty Pharma may well be the solution to many of Big Pharma’s current woes. Its success driven largely by astute manipulation of the business and market issues that \| more...	5/31/2007	$1,112.50
Oncology Pipelines: Is the Future Targeted Therapy? By: Decision Resources Drug companies’ cancer pipelines are bulging, and hundreds of new drugs are in development--the modern equivalent of a gold rush. Remarkable successes have been recorded with targeted oncology, but the treatment of more than 200 \| more...	5/31/2007	$1,112.50
Clinical Proteomics: Rethinking Approaches to Protein Biomarker Discovery By: Decision Resources Protein biomarkers are appealing to drug developers because they can be used early in the drug research pipeline, which allows early elimination of ineffective or toxic compounds. Although the promise of these biomarkers is clear, \| more...	5/31/2007	$1,112.50
The Challenges of Reference Pricing in Europe By: Decision Resources In 1989, the German government introduced reference pricing as a cost-containment strategy for the pharmaceutical industry’s high prices of drugs. Now, much of Europe employs reference pricing as a means to rein in the prices \| more...	5/28/2007	$1,112.50
Drug Repositioning Strategies for Refueling the Pipeline By: Decision Resources Drug companies have historically found new indications for their existing drugs serendipitously. Now, however, to refuel product pipelines and improve profi t margins, many companies are turning to low-risk strategies such as drug repositioning. Biotech \| more...	5/24/2007	$1,112.50
SPECIAL REPORT: Getting Maximum Benefit from Combination Products By: Decision Resources Combination products are a lifeline in today’s pharmaceutical industry, but not all are created equal. Many companies use combinations late in the product life cycle to extend patent life or to maximize revenues, but more-successful \| more...	5/23/2007	$2,250.00
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the First Quarter of 2007 By: Decision Resources In the first quarter of 2007, political intervention in drug pricing and reimbursement in the world’s major pharmaceutical markets greatly increased. In the United States, for example, a new Democratic majority in Congress is intent \| more...	5/3/2007	$1,112.50
Drug-Eluting Stents: Can the Market Rebound from Recent Setbacks? By: Decision Resources A few years after their introduction in 2002, drug-eluting stents had all but replaced bare-metal stents in the treatment of coronary heart disease, capturing up to 90% of the market. Physicians favored the new stents \| more...	4/27/2007	$1,112.50
Cancer Biomarkers: New Tools for Transforming Cancer Management By: Decision Resources Although novel cancer biomarkers are reported on a weekly basis, only a handful are actually translated into fully validated diagnostic tools. To fully understand the process, we explore the current status of the cancer biomarker \| more...	4/20/2007	$1,112.50
Generics Erosion Patterns in the U.S. Market By: Decision Resources With an estimated $51 billion of branded drugs coming off patent between 2006 and 2011, both U.S. government insurance plans and private, third-party payers will promote increased use of generics in the future. In a \| more...	4/3/2007	$1,112.50
Are Biologics the Wave of the Future? By: Decision Resources Biologics have been good to the pharmaceutical industry—a trend that will continue for the foreseeable future as a raft of new and improved biologics comes to market. Some companies rode the crest of the biologics \| more...	3/30/2007	$1,112.50
Overcoming Challenges in Antibacterial Drug Discovery and Development By: Decision Resources The antibacterial market is highly mature, yet there is a compelling need to discover new antibacterials to combat the escalating threats of drug resistance, the threats posed by new and reemerging pathogens, and bioterrorism threats. \| more...	3/30/2007	$1,112.50
Bipolar Disorder: Can Competitive Advantage Be Established in a Challenging Market By: Decision Resources A poorly understood, complex disease that involves a number of neurotransmitters, bipolar disorder presents several challenges for pharmaceutical companies seeking to develop new treatments. While lithium and several antiepileptic and antipsychotic agents are currently used \| more...	3/26/2007	$1,112.50
Updated CDC HIV Testing Guidelines to Shape Evolving Diagnostics Market By: Decision Resources HIV/AIDS stands out as a highly lucrative and expanding market for diagnostics companies because of the close integration of diagnostics in initial diagnosis and subsequent day-to-day disease management. With the newly released CDC screening recommendations \| more...	3/26/2007	$1,112.50
Specialty Pharmaceuticals in the United States: Changing Patterns of Distribution and Reimbursement By: Decision Resources Specialty pharmaceuticals are among the most expensive products in health plans' pharmacy budgets. Thus, the provision and use of these drugs in both the commercial insurance and Medicare arenas is of great interest to several \| more...	3/26/2007	$1,112.50
Challenges in Oncology Clinical Design By: Decision Resources The ongoing evolution of cancer therapeutics and the associated increase in survival times have prompted a reevaluation of traditional methodology in the design and conduct of oncology clinical trials. These changes have led to increasing \| more...	3/26/2007	$1,112.50
Executing Change in the Pharma Industry - Prescription for Pfizer By: Decision Resources Pharmaceutical history is littered with the abandoned husks of great ideas, many costing a king's ransom and never able to live up to their promise. Indeed, there is little doubt that in recent years pharmaceutical \| more...	3/23/2007	$1,112.50
Confronting the Bioprocessing Challenge By: Decision Resources In the early 2000s, an anticipated shortfall in protein production capacity was averted thanks to breakthroughs in manufacturing approaches and technologies. Today, new challenges and bottlenecks threaten the costeffective and adequate manufacture of protein therapeutics-which \| more...	3/20/2007	$1,112.50
Recent Advances in the Fast-Growing Molecular Diagnostics Industy By: Decision Resources Molecular diagnostics (MDx) is becoming increasingly entwined with the development of pharmaceutical drugs. Initially, it was used in clinical settings to aid diagnosis, prognosis, and optimal treatment, but now, backed by regulatory authorities, it is \| more...	3/16/2007	$1,112.50
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Fourth Quarter of 2006 By: Decision Resources Implementation and refinement of existing pricing and reimbursement initiatives throughout the major pharmaceutical markets continued to be a major theme in the fourth quarter of 2006. In the United States, preparations continued for the second \| more...	3/8/2007	$1,112.50
The Anemia Market: Biogenerics and Second-Generation Products Drive Change By: Decision Resources The availability of recombinant biologic agents has revolutionized the treatment of anemia and has created a market with a small number of players. However, the inconvenient administration and high prices of these biologic agents represent \| more...	3/7/2007	$1,112.50
Title	Published	Price

< prev 1 2 3 4 5 6 7 8 9 10 next >

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/22/2009 - 4